Followers | 822 |
Posts | 163138 |
Boards Moderated | 6 |
Alias Born | 09/23/2009 |
Wednesday, August 10, 2016 8:47:59 AM
KELOWNA, BC / ACCESSWIRE / August 10, 2016 / Lexaria Bioscience Corp. (OTCQB: LXRP) (CSE: LXX) ("the Company" or "Lexaria") has entered a letter of intent (LOI) to license its proprietary technology to CBDM LLC for the development and sale of a range of marijuana oil infused products in a potentially national-scale roll-out to Indian reservations across America and certain other U.S. territories.
Under the terms of the LOI, usage fees of $200,000 are contemplated for each product line introduced, over a five-year operating term per state. The Licensee can earn non-exclusive rights to sell up to five product lines on Indian reservations, through licensed medical or adult use retailers only. Currently, 35 states have federally recognized Indian reservations. The Licensee may also earn non-exclusive rights to sell these product lines in all areas of Massachusetts, Pennsylvania, Arizona and Nevada.
Technology license usage fees payable to Lexaria have the potential to reach as much as $36,000,000 over the term of the seven-year agreement, though the actual amount to be paid shall depend on the number of product lines and states the Licensee ultimately effects.
The LOI further contemplates a $175,000 per-state payment by the Licensee, to be paid in-kind to Lexaria by executing clinical testing in patients receiving products with Lexaria's technology. This clinical testing will be conducted and funded by researchers affiliated with the Licensee at a major US University and Lexaria will have access to study data and results. Lexaria's technologically enhanced products will be evaluated for their efficacy in alleviating certain symptoms associated with chronic disease to be studied, in concert with primary intervention treatment. Lexaria will begin collaborations with the Licensee and its affiliated university researchers on the basic design elements of the planned clinical testing. Lexaria will have no funding responsibilities for the clinical testing and does not influence its funding sources which are third-party to the Company.
Under this structure, total in-kind fees of $6,300,000 would grant the Licensee access to valid sales territories in each of the 36 states mentioned.
Additional information and details regarding these clinical testing plans will be announced in due course. Readers are cautioned that the clinical plans are currently in the preliminary design stages and will, like any other clinical testing in patients with chronic disease, likely take an as yet undetermined period of many months to complete and report.
"We are extremely pleased to have effected this LOI with our second prospective licensee in the medical and adult use marijuana edibles sector," said John Docherty, President of Lexaria Bioscience Corp. "Lexaria was recently granted its first patent allowance by the US Patent and Trademark Office, and is heartened to observe the response of the marketplace as it acknowledges the value of the Lexaria technology in improving flavor and performance of cannabinoids and other bioactive substances in consumer products. Lexaria feels confident that it will succeed in being awarded additional new patent allowances in 2016 and 2017 that will further strengthen its competitive position in the marketplace and its ability to effect additional revenue generating technology out-licensing agreements pursuant to its business plan within the cannabis sector and beyond."
Lexaria itself is not selling any products through this agreement. The LOI is expected to advance into a definitive agreement within 60 days though there is no assurance of this. Additional information will be released regarding the completion of the definitive agreement, and progress with the clinical testing, as they are confirmed and available. Readers are cautioned that a definitive agreement has not yet been reached and, even if reached, receipt of license usage fees is dependent upon the success of the Licensee in launching and operating their business.
About Lexaria
Lexaria Bioscience Corp. is a food sciences company focused on the delivery of active compounds that can behave as superfoods through its proprietary infusion technologies. Lexaria's technology enables higher bioavailability rates for CBD; THC; NSAIDs; Nicotine and other molecules than is possible without lipophilic enhancement technology. This can allow for lower overall dosing requirements and/or higher effectiveness in active molecule delivery. Lexaria hopes to reduce other common but less healthy ingestion methods such as smoking as it embraces the benefits of public health. www.lexariaenergy.com
Recent LEXX News
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/06/2024 11:00:40 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/01/2024 07:28:18 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/16/2024 09:30:59 PM
- Form D - Notice of Exempt Offering of Securities • Edgar (US Regulatory) • 02/16/2024 08:47:26 PM
- Form SC 13D/A - General statement of acquisition of beneficial ownership: [Amend] • Edgar (US Regulatory) • 02/14/2024 07:20:50 PM
- Form SC 13G/A - Statement of acquisition of beneficial ownership by individuals: [Amend] • Edgar (US Regulatory) • 02/14/2024 05:00:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/30/2024 06:51:13 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/24/2024 07:12:07 PM
- Form POS AM - Post-Effective amendments for registration statement • Edgar (US Regulatory) • 01/24/2024 06:33:08 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 01/18/2024 07:38:18 PM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 01/12/2024 10:11:16 PM
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Proprietary Drug-Delivery System Improves Way Molecules Enter Bloodstream • GlobeNewswire Inc. • 01/11/2024 01:30:00 PM
- Beyond Diabetes, a Blockbuster Horizon Beckons • InvestorsHub NewsWire • 01/10/2024 01:45:00 PM
- Lexaria Bioscience Corp. (NASDAQ: LEXX) Improves Delivery, Efficacy of GLP-1 Agonists Through Proprietary Drug-Delivery Platform • GlobeNewswire Inc. • 01/09/2024 01:30:00 PM
- Exciting New Cures Possible from GLP-1 Diabetes, Weight-Loss Drugs • InvestorsHub NewsWire • 01/08/2024 01:45:00 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/04/2024 10:07:45 PM
- Form S-1 - General form for registration of securities under the Securities Act of 1933 • Edgar (US Regulatory) • 11/30/2023 09:14:31 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 11/20/2023 10:16:25 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/03/2023 05:13:38 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/01/2023 05:45:34 PM
- Get Ready for Next Generation of Diabetes, Weight-Management Drugs • InvestorsHub NewsWire • 11/01/2023 12:45:00 PM
Avant Technologies Equipping AI-Managed Data Center with High Performance Computing Systems • AVAI • May 10, 2024 8:00 AM
VAYK Discloses Strategic Conversation on Potential Acquisition of $4 Million Home Service Business • VAYK • May 9, 2024 9:00 AM
Bantec's Howco Awarded $4.19 Million Dollar U.S. Department of Defense Contract • BANT • May 8, 2024 10:00 AM
Element79 Gold Corp Successfully Closes Maverick Springs Option Agreement • ELEM • May 8, 2024 9:05 AM
Kona Gold Beverages, Inc. Achieves April Revenues Exceeding $586,000 • KGKG • May 8, 2024 8:30 AM
Epazz plans to spin off Galaxy Batteries Inc. • EPAZ • May 8, 2024 7:05 AM